Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04140396 · ClinicalTrials.gov registry record · Phase 4
Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia
A Phase 4 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT04140396: Clinical Trial Phase 4 study, sponsored by Stanford University.
NCT04140396 is a Phase 4 study that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04140396, a Phase 4 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of delirium. In the past few decades, intravenous lidocaine infusion (IVL) has emerged as a new tool in the arsenal of multimodal analgesia. Multiple randomized clinical trials have indicated that IVL is overall well tolerated and have shown other beneficial effects such as anti-inflammatory properties. To this date, there have been no published randomized clinical trials (RCT) evaluating the effectiveness of IVL in management of traumatic rib fracture pain. Therefore, the purpose of this study is to evaluate whether IV Lidocaine infusion can provide improved pain control as demonstrated by decreased OME consumption at 24 and 48 hours compared to placebo in adult patients with acute traumatic rib fractures.
Interventions
- DRUG Saline infusion
- DRUG Lidocaine infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04140396
The ClinicalTrials.gov registry entry for NCT04140396 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline infusion is the first listed.
NCT04140396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04140396 about?
NCT04140396 is a clinical study titled "Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia". The current cornerstone of pain control for rib fractures is oral and intravenous opioids, especially in the form of patient-controlled analgesia (IV PCA), which are are associated with multiple adverse effects including sedation, respiratory depression, cough suppression, and increased risk of deli...
What is the current status of trial NCT04140396?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2020-02-10. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT04140396?
The interventions under investigation include: Saline infusion (DRUG), Lidocaine infusion (DRUG).
Who is sponsoring clinical trial NCT04140396?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.